期刊文献+

基于病人报告的结局测量在类风湿关节炎疗效评价中的作用 被引量:3

The Effect of Patient-Reported Outcome in RA Curative Evaluation
原文传递
导出
摘要 以往建立在生物医学模式基础上的RA临床评价体系,多关注的是医生对病情活动性的评价及生物医学指标,而缺乏对病人的自觉症状和健康有关的生存质量为代表的生物-心理-社会健康状态的观测和评价。目前现有的RA评价方法,不能完全获取包括RA病人主观感受及疾病痛苦程度在内的疾病状态的信息,亦不能全面反映药物干预对疾病状态的调整程度。基于病人报告的结局指标(patient reported outcomes,PRO)通过捕捉与病人健康相关的疾病相关信息,从病人报告的侧面反映病人的疾病状态,将在RA临床疗效评价中发挥重要作用,成为现有临床疗效评价方法的重要补充。 The clinical evaluation system based on the bilogical medical model in the past paid more attention to the doc-tors’evaluation on the activity of the disease and the biomedicine index.This system ignored the patients themselves’evaluations to the rational symptom and the life quality correlated to the health.The existed evaluational method in RA could not complete-ly acquire the disease informations including the patients’subjective recepions and the complaint level,and it could not com-pletely reflect the medicine effect.Patient-Reported Outcome(PRO) captured the disease informations related to the pa-tients’health,and it reflected the morbid state from the viewes coming from the patients.Therefor,PRO will play the impor-tant role in RA clinical evaluation,and become the important addition for the evaluational method in RA clinic
出处 《中华中医药学刊》 CAS 2010年第11期2273-2274,共2页 Chinese Archives of Traditional Chinese Medicine
基金 国家科技部基础平台建设项目(2004DEA71040)
关键词 类风湿关节炎 病人报告结局 疗效评价 Rheumatoid Arthritis Patient - Reported Outcomes Evaluation of Curative Effect
  • 相关文献

参考文献10

  • 1Scott DL, Symmons DP, Couhon BL, el al. Long- term outcome of treating rheumatoid arthritis: results after 20 years[ J]. Lancet, 1987,1:1108 - 1111.
  • 2Pincus T. , Bergman M. J. ,Yazici Y. , et al. An index of only patient - reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score ( DAS28 ) and other RAPID indices that include physician - reported measures [ J ]. Rheumatology,2008 ,47 :345 349.
  • 3Pincus T,Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count[J]. Ann Rheum Dis, 2006, 65:820-822.
  • 4U. S. Department of Health and Human Services Food and Drug Administration. Contains Nonbinding Recommendations. Patient -reported outcome measures: use in medical product development to support labeling clairms [ S ]. Guidance for Industry, 2006 :2.
  • 5FDA. Giudelines for the clinical evaluation of anti - inflammator and antirheumatic drugs (adults and children) [ S]. April, 1988.
  • 6Paulus HE,Egger MJ,Wand JR,et al. Analysis of improvemen in individual rheumatoid arthritis patients treated with disease - modifying antirheumatic drugs based on findings in patients with placebo[ J ]. Arthritis Rheum, 1990,33:477 - 484.
  • 7Felson DT, Anderson J, Boers M, et al. American College of Rheumatology preliminary defination of improvement in rheumatoid arthritis [ J ]. Arthritis Rheum, 1995,38 : 727 - 735.
  • 8Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials[J]. J Rheumatol,2007,15 :632 -640.
  • 9谭玉珍,吴彩玲,游运辉.甲氨喋呤联合青霉胺治疗类风湿性关节炎临床分析[J].中国现代医学杂志,2000,10(12):71-72. 被引量:9
  • 10U Kalyoncu, M Dougados, J - P Daures, et al. Reporting of patient -reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review[ J]. Ann Rheum Dis,2008, 3 : 1060 - 1066.

二级参考文献4

共引文献8

同被引文献31

引证文献3

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部